Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1911-1913

  Tong, Xiuzhen ^a   Li, Juan ^a   Zhou, Zhenhai ^a   Zheng, Dong ^a   Liu, Junru ^a   Su, Chang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DECITABINE; HEMOGLOBIN; MITOXANTRONE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ATYPICAL CHRONIC MYELOID LEUKEMIA; BLOOD SMEAR; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELL STRUCTURE; CHROMOSOME ANALYSIS; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TOXOPLASMOSIS; ANALOGS AND DERIVATIVES; ANEMIA; CHEMICALLY INDUCED; CHROMOSOME ABERRATION; FATALITY; GENETICS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; PATHOLOGY; REMISSION; TREATMENT OUTCOME;

ADULT; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMOSOME ABERRATIONS; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MIDDLE AGED; REMISSION INDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84932146434     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.986477     Document Type: Letter

References (12)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
2. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008; 22: 1308-1319.
3. Breccia M, Biondo F, Latagliata R, et al. I dentification of risk factors in atypical chronic myeloid leukemia. Haematologica 2006; 91: 1566-1568.
4. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
5. Braun T, Itzykson R, Renneville A, Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase 2 trial. Blood 2011; 118: 3824-3831.
6. Hernandez JM, del Canizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000; 11: 441-444.
7. Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
8. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
9. KoldehoffM, Steckel NK, Hegerfeldt Y, et al. Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. Int J Lab Hematol 2012; 34: e3-e5.
10. Xubo G, Xingguo L, Xianguo W, et al. The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy indistinguishing atypical chronic myeloid leukemia. from chronic granulocytic leukemia and chronic myelomonocytic leukemia. Eur J Haematol 2009; 83: 292-301.
11. Fend F, Horn T, Koch I, et al. A typical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leuk Res 2008; 32: 1931-1935.
12. KoldehoffM, Beelen DW, Trenschel R, et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant 2004; 34: 1047-1050.